

## **BLUE EARTH DIAGNOSTICS ANNOUNCES OPENING OF U.S. OFFICE AND EXPANSION OF MANAGEMENT TEAM**

May 13, 2016

---

**OXFORD, England, and BURLINGTON, Mass. – May 11, 2016** – Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced that it has established operations in the United States at 25 Burlington Mall Road, Suite 404, in Burlington, Mass. Blue Earth Diagnostics is dedicated to developing and commercializing innovative PET imaging products that address unmet needs in cancer. The Company also announced the creation of key appointments for Blue Earth Diagnostics Inc.: Michael W. Heslop, as President; Peter Gardiner, MB ChB, MRCP, FFPM, as Vice President, Medical Affairs; Bradley K. Pounds as Vice President, Sales, U.S.; David Pendleton, Vice President, Marketing; Christa Dhimo, Vice President, Strategy & Execution U.S.; and Priscilla Harlan, Vice President, Corporate Communications. Blue Earth Diagnostics Inc. is a wholly-owned subsidiary of U.K.-based Blue Earth Diagnostics Ltd.

“A strong presence in the United States is a critical next step in Blue Earth’s mission to deliver new molecular imaging agents to cancer patients with unmet medical needs,” said Jonathan Allis, D.Phil., CEO of Blue Earth Diagnostics Ltd. “With our lead PET imaging product candidate, fluciclovine F 18, in Priority Review with the U.S. Food and Drug Administration, we need to plan for its potential approval and for future growth. Mike Heslop has been leading the U.S. team as President of Blue Earth Diagnostics Inc. With his leadership and that of the other proven industry leaders who have recently joined the Company, we believe we are well-positioned for success and we are excited about the future.”

“Blue Earth’s headquarters in Massachusetts will provide sales, marketing and medical affairs support for the development and commercialization of fluciclovine F 18 in the important U.S. market,” said Michael W. Heslop, President of Blue Earth Diagnostics Inc. “We are very pleased to be in Massachusetts and we look forward to being an active and productive member of the Burlington and Massachusetts business communities.”

*Michael W. Heslop, President, Blue Earth Diagnostics Inc.*

Mr. Heslop is the President of Blue Earth Diagnostics Inc. and has more than 25 years of experience in commercial and general management with Glaxo Wellcome USA, Genzyme Corporation and, most recently, Lantheus Medical Imaging, where he was Vice President Business Development and Strategy. While at Genzyme, he held the positions of Senior Vice President & General Manager of the Biosurgery and Endocrine businesses, and Vice President,

Global Marketing, PGH Business. Mr. Heslop received a B.Sc. degree in Biology from McGill University and an M.B.A. from Concordia University.

***Peter Gardiner, MB ChB, MRCP, FFPM, Vice President, Medical Affairs***

Dr. Gardiner is responsible for the medical and scientific support of all commercial activities in the United States. His more than 30 years of industry experience has included clinical research and medical affairs roles of increasing responsibility with GD Searle, Gensia, DuPont Pharmaceuticals, Bristol-Myers Squibb, BG Medicine and Navidea Biopharmaceuticals. A graduate of Leeds University Medical School, Dr. Gardiner is a Member of the Royal College of Physicians and a Fellow of its Faculty of Pharmaceutical Medicine.

***Bradley K. Pounds, Vice President, Sales U.S.***

Mr. Pounds has more than 30 years of experience in diagnostic imaging, including radiopharmaceuticals and contrast agents used for ultrasound and magnetic resonance imaging. He has led multifunctional teams in marketing, medical affairs and sales for both large and small pharmaceutical companies, including Lantheus Medical Imaging, Lilly USA and Navidea Biopharmaceuticals. Mr. Pounds has a Bachelor of Science degree from the University of Houston.

***David Pendleton, Vice President, Marketing***

Mr. Pendleton has more than 30 years of experience in diagnostic imaging and radiopharmaceuticals and has held numerous commercial leadership positions in marketing, sales and business development, including executive positions at New England Nuclear, DuPont Medical Imaging, Bristol-Myers Squibb, Theseus Imaging, inVentiv Health, Lantheus Medical Imaging and Navidea Biopharmaceuticals. He has consulted for a variety of companies across numerous therapeutic specialties. Mr. Pendleton has a Bachelor of Science degree from Northeastern University.

***Christa Dhimo, Vice President, Strategy & Execution U.S.***

Ms. Dhimo has more than 20 years of experience in setting and executing global growth and performance strategies. She has led many initiatives across various industries in companies both large and small such as Fidelity Investments, [Salary.com](https://www.salary.com) (an IBM Company), Raytheon, and, most recently, Lantheus Medical Imaging where she was the Senior Director of Strategic Programs. Ms. Dhimo is a PMP® and received a BA from the University of Massachusetts, an MBA from Northeastern University and a Master in Management – Informatics from the University of Dallas. She also holds a Master Certificate in Strategic Organizational Leadership from Villanova University.

***Priscilla Harlan, Vice President, Corporate Communications***

Ms. Harlan has more than 25 years of communications experience in the life sciences industry, including executive positions at Lantheus Medical Imaging, Molecular Insight Pharmaceuticals and Sepracor (now Sunovion) and agency leadership positions at Feinstein Kean Healthcare (Ogilvy) and Complete Healthcare Communications. She has consulted to companies across a spectrum of therapeutic areas. Ms. Harlan has a Bachelor of Arts degree in Biology and History from the University of North Carolina.

The address for Blue Earth Diagnostics Inc. is 404 Burlington Mall Road, Suite 404, Burlington, Mass. 01803. The Company's main telephone number is (855) 298-6461.

### **About Blue Earth Diagnostics**

Blue Earth Diagnostics is a molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Blue Earth Diagnostics' most advanced investigational product candidate is fluciclovine F 18, in development for use with PET imaging in patients with biochemically recurrent prostate cancer. The Company is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. Blue Earth Diagnostics Inc. of Burlington, Mass., is the wholly-owned U.S. subsidiary of U.K.-based Blue Earth Diagnostics Ltd. The Company is funded by Syncona LLP, an independent subsidiary of the Wellcome Trust. For more information, visit: [www.blueearthdx.com](http://www.blueearthdx.com).

### **Contact:**

#### **For Blue Earth Diagnostics Inc. (U.S.)**

##### **Corporate Communications**

Priscilla Harlan

Vice President, Corporate Communications

781-799-7917

[p.harlan@blueearthdx.com](mailto:p.harlan@blueearthdx.com)

##### **Media**

Sam Brown Inc.

Cory Tromblee

617-571-7220

[corytromblee@sambrown.com](mailto:corytromblee@sambrown.com)